Michael Kors Holdings Ltd (NYSE:KORS) engages in the design, marketing, distribution, and retailing of branded women’s apparel and accessories, and men’s apparel. The company operates in three segments: Retail, Wholesale, and Licensing. KORS has a PE ratio of 32.0. Currently there are 10 analysts that rate Michael Kors Holdings a buy, 2 analysts rate it a sell, and 3 rate it a hold. Michael Kors Holdings Ltd (NYSE:KORS) stock opened today at $ 95.04 and is currently trading at $ 96.20. The stock showed a negative weekly performance of 0.83%.
Timothy Fenton will retire from McDonald’s Corporation (NYSE:MCD) on June 30, 2014. In connection with his retirement, the Compensation Committee of the Board of Directors of the Company agreed to waive certain notice and service requirements pursuant to the terms of his outstanding compensation awards. These waivers will permit Mr. Fenton, upon retirement, to qualify for retirement treatment pursuant and otherwise subject to the terms of his respective awards, and in addition, with respect to his 2014 stock option and RSU awards, he will receive credit for service through March 1, 2015. Mr. Fenton will also receive a lump-sum payment of $375,000, payable on December 30, 2014. McDonald’s Corporation (NYSE:MCD) stock opened at $ 101.84, in current trading session and currently is at $ 101.20, by losing -1.13%. The 52 week range of $ 92.22 – $103.78. Company’s market capitalization is $ 100.03 billion.
Toll Brothers Inc. (NYSE:TOL) will build state of the art 274 single family houses on a 173 acre plot. The entire project will be located near the southern end of Ford Road, between Napier and Ridge. Incidentally, this will be a maiden venture for Toll Brothers in the Canton Region. Toll Brothers Inc. (NYSE:TOL) stock is currently trading at $ 36.43. The EPS of the stock is 1.17. Company’s market capitalization is $ 6.47 billion.
Dyax Corp. (NASDAQ:DYAX) announced dosing of the first subject in its Phase 1b clinical study of DX-2930 in hereditary angioedema (HAE) patients. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of multiple subcutaneous administrations of DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein. Dyax, a biopharmaceutical company focused on HAE and other plasma-kallikrein-mediated disorders, is developing DX-2930 as a subcutaneous injection for prevention of HAE attacks. Dyax Corp. (NASDAQ:DYAX) stock opened the session at $8.40, and now is at $ 8.63. The 52 week range of the DYAX stock remained $ 2.65 – $10.99 and the day range was $ 8.22 – $ 8.69.
Leave a Reply